Characteristics of gram-negative urinary tract infections caused by extended spectrum beta lactamases: pivmecillinam as a treatment option within South Dublin, Ireland by Fardod O’Kelly et al.
RESEARCH ARTICLE Open Access
Characteristics of gram-negative urinary
tract infections caused by extended
spectrum beta lactamases: pivmecillinam
as a treatment option within South Dublin,
Ireland
Fardod O’Kelly2†, Siobhan Kavanagh1†, Rustom Manecksha2, John Thornhill2 and Jérôme P. Fennell1*
Abstract
Background: The prevalence of urinary tract infections (UTIs) caused by extended-spectrum β-lactamase (ESBL)-
producing Enterobacteriaceae is increasing and the therapeutic options are limited, especially in primary care.
Recent indications have suggested pivmecillinam to be a suitable option. This pilot study aimed to assess the
viability of pivmecillinam as a therapeutic option in a Dublin cohort of mixed community and healthcare origin.
Methods: A prospective measurement of mean and fractional inhibitory concentrations of antibiotic use in 95
patients diagnosed with UTI caused by ESBL-producing Enterobacteriaceae was carried out. 36 % patients were
from general practice, 40 % were admitted to hospital within south Dublin, and 25 % samples arose from nursing
homes. EUCAST breakpoints were used to determine if an isolate was sensitive or resistant to antibiotic agents.
Results: Sixty-nine percent of patients (N = 66) with urinary ESBL isolates were female. The mean age of females
was 66 years compared with a mean age of 74 years for males. Thirty-six percent of isolates originated from primary
care, hospital inpatients (26 %), and nursing homes (24 %). The vast majority of ESBL isolates were E. coli (80 %). The E
tests for mecillinam and co-amoxiclav had concentration ranges from 0.16 mg/L up to 256 mg/L. The mean inhibitory
concentration (MIC) of mecillinam ranged from 0.25 to 256 mg/L, while co-amoxiclav MICs ranged from 6 to 256 mg/L.
The percentage of isolates resistant to mecillinam and co-amoxiclav was found to be 5.26 and 94.74 % respectively.
Conclusions: This is the first study exploring the use of pivmecillinam in an Irish cohort and has demonstrated that its
use in conjunction with or without co-amoxiclav is an appropriate and useful treatment for urinary tract infections
caused by ESBL-producing organisms.
Keywords: Extended-spectrum beta lactamase, Pivmecillinam, Antibiotic resistance, Urinary tract infection, Mean
inhibitory concentration, Escherichia coli
* Correspondence: jfennell@tcd.ie; jerome.fennell@amnch.ie
†Equal contributors
1Department of Clinical Microbiology, AMNCH, Tallaght Hospital, Dublin 24,
Ireland
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
O’Kelly et al. BMC Infectious Diseases  (2016) 16:620 
DOI 10.1186/s12879-016-1797-3
Background
Microorganisms constantly evolve resistance to antimi-
crobials, rendering current agents ineffective. This is
compounded by the reality that there are few new anti-
microbials in development. Extended-spectrum beta
lactamase (ESBL) producing organisms are one of the
resistance types of most concern. ESBLs were first recog-
nized in the 1980s due to point mutations of Temoneira
(TEM) and Sulphydryl Variable (SHV) broad-spectrum
enzymes genes. A common causes of hospital-acquired in-
fections especially in the intensive care unit, ESBLs also
commonly carry resistance to other antimicrobials such as
quinolones, cotrimoxazole and the aminoglycosides. This
further limits treatment options. Laboratory diagnosis of
ESBLs is complex and normally performed by screening
and phenotypic tests [1].
Traditionally ESBL producing bacteria were associ-
ated with nosocomial infection, but they are now
widespread in the community. In the UK, community
ESBLs were mostly isolated during urinary infections
the elderly, who had recent hospitalisation [2]. In con-
trast, an Irish study found that 42 % of community iso-
lates that were ESBL producing, were from individuals
not in long term care or hospitalised in the previous
year [3]. Risk factors for acquiring community associ-
ated ESBL infections include recurrent UTI, previous
antibiotic usage, diabetes and prior instrumentation to
urinary tract [1, 4].
ESBLs were first detected in Western Europe, where β-
lactam antibiotics were first used, with prevalence varying
between countries. In 2001, the Netherlands had a low per-
centage of ESBL producing Enterobacteriaceae with only
1 % of E. coli and K. pneumoniae being ESBL positive. In
contrast 40 % of France’s K. pneumoniae were ceftazidime
resistant. ESBL producers are normally multiple drug resist-
ant and have become an important mechanism of β-lactam
resistance in community uropathogens [5]. Production of
β-lactamase is the most common resistance mechanism
of bacteria to β-lactam antibiotics [6]. E. coli resistance
is mostly due to production of β-lactamases, which
hydrolyze the beta-lactam ring of beta-lactam antibi-
otics such as penicillin. Resistance to ampicillin and
amoxicillin is normally due to plasmid-coded β-
lactamases the majority of which is the TEM type [7].
ESBLs have resistance to β-lactams, ampicillin, amoxi-
cillin and third generation cephalosporins. The ESBL
carrying plasmid often carries other resistance genes as
well, e.g. resistance genes to quinolones and aminoglyco-
sides. When this occurs usage of any of the classes of anti-
microbials that the plasmid encodes resistance to will
select for this multiple resistant isolate. The first ESBLs in
E. coli were variants of the TEM or SHV β-lactamases,
which could hydrolyze cefotaxime, ceftriaxone and ceftazi-
dime, however the CTX-M-type bla gene has now
become the commonest type. The CTX-M enzymes also
appear to have a greater ability to spread and cause out-
breaks [2, 8, 9]. CLSI recommendations state to only
check for ESBLs in E. coli, Klebsiella pneumoniae, K. oxy-
toca and Proteus mirabilis, but all Gram-negative bacteria
can be ESBL positive. In 2006, two E. coli ESBL isolates
were associated with UTIs from two residents in an Irish
nursing home. On review, five more patients in that nurs-
ing home were found to be ESBL positive [10]. This is a
typical example of the transmission of antibiotic resistant
bacteria in a vulnerable group of patients where long-term
isolation is not viable and there is a need to control the
spread of these organisms. A more recent study surveyed
an Irish nursing home and found over 55 % of residents
were colonized by ESBL producers [11]. In Ireland in
2015, 10.6 % of invasive E. coli and 13.3 % of invasive K.
pneumoniae isolates were found to be ESBL Positive, the
highest annual percentage to date [12].
There is a lack of effective therapeutic options to com-
bat ESBLs. Carbapenems, often regarded the antibiotic of
choice, should be used when there are no other options
available but their use inevitably leads to the emergence of
carbapenem-resistant enterobacteriaciae (CRE). Fluoro-
quinolones, can be effective against ESBLs, but are not
recommended for routine use due to resistance rates.
Aminoglycosides, also effective, should not be used for
monotherapy in serious infections, as they are bacterio-
static. Colistin should be used with caution, as it is a
broad-spectrum agent. The potential nephrotoxicity of
these agents is another concern in this setting and is an-
other reason to limit their use. Tigecycline demonstrates
good in vitro activity against ESBLs but the FDA has
warned against its use due to the increased mortality in
Tigecycline-treated patients, as well as its relative ineffi-
cacy in pneumonia and bacteraemia, as well as limited GU
tract concentrations [13, 14]. Fosfomycin, an old broad-
spectrum antibiotic, has been re-evaluated for the treat-
ment of UTIs due to multidrug resistant organisms. It is
only licensed for lower uncomplicated UTIs and may de-
velop resistance [15].
Pivmecillinam, a β-lactam antibiotic, the prodrug of
mecillinam, is hydrolyzed to the active agent mecillinam
[16]. Mecillinam must be administered parentally but
oral pivmecillinam is available. Its mode of action is to
bind to penicillin-binding protein 2 in Enterobacteria-
ceae and inhibit bacterial cell wall synthesis [17]. It has
high activity against many Gram-negative bacteria such
as E. coli, Klebsiella sp., Salmonella sp. and Enterobacter
sp. and has limited activity against some Gram positives.
The use of pivmecillinam for more than 20 years in Nor-
dic countries confirms its efficiency and safety in treat-
ing UTIs. Its oral bioavailability makes it an attractive
option without requiring hospital admission for intra-
venous treatment [16, 18].
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Antibiotic resistance is a concerning public health
problem that increases morbidity and mortality. Novel
drug development is time-consuming, but re-evaluating
antibiotics already licensed is more time-effective [17].
Combination therapy is of interest as multi drug resist-
ant microorganisms may require more than one anti-
biotic to treat successfully [19]. Unfortunately, there are
limited oral antibiotics available for complicated UTIs
caused by ESBL and AmpC producing bacteria [15].
This clinical study examines the antimicrobial suscep-
tibility of 95 ESBL producing isolates to pivmecillinam
and co-amoxiclav in a tertiary referral center, to deter-
mine if our catchment population could benefit with
combination treatment of ESBL urinary tract infection.
Methods
This study received approval from the hospital ethics com-
mittee and the research carried out was also in compliance
with the Helsinki Declaration. Clinico-demographic data
was collated on 95 patients that had tested positive for
ESBL urinary infection at the department of Microbiology,
Tallaght hospital (2012–2013). Isolates had previously been
confirmed as ESBLs by MASTDISCS ID AmpC and ESBL
inhibitors and MASTDISCS cefepime ESBL ID for the
Vitek 2. E-tests were performed on ESBLs that were ini-
tially stored on beads in an −18 °C freezer, and then plated
on MacConkey agar and incubated at 37 °C for 24 h. All
isolates were then subcultured onto nutrient agar slopes.
One mecillinam and one co-amoxiclav E test were then
each applied with forceps onto the plate. The elliptical
zones of inhibition were read to determine the MIC of E.
coli according to the manufacturer instructions. The MIC
was read as the point where the ellipse intersected the E
test strip. If the intersect was different on both sides the
greater value was taken as the MIC.
A checkerboard method was also used to assess the
mean inhibitory concentrations (MIC) of each positive
ESBL sample by measuring the spectrophotometric ab-
sorbance of each well 16 to 24 h following inoculation
using an ELX800 universal micro plate reader at a wave-
length of 630 nm. The percentage of growth was calcu-
lated on the basis of colour absorbance using (OD630 of
wells that contained the drug/OD630 of the drug-free
well). The MICs of the drugs alone and of in combin-
ation were determined as the lowest drug concentrations
showing <10 % of the growth of an untreated control
[20, 21].
For each combination of antibiotics the fractional in-
hibitory concentration was calculated which is a pre-
dictor of synergy [22]. The fractional inhibitory
concentration (FIC) was used to evaluate the effective-
ness of the combinations. The formulas used were FIC
of drug A (mecillinam) =MIC drug A in combination/
MIC drug A alone; FIC of drug B (co-amoxiclav) =MIC
drug B in combination/ MIC drug B alone and FIC
index = FIC drug A + FIC drug B. Synergy was defined as
FIC index of ≤0.5, indifference of FIC as >0.5 but of ≤4.
Antagonism was defined as FIC index of >4. All experi-
ments were performed in triplicate.
EUCAST (European Committee on Antimicrobial Sus-
ceptibility Testing) breakpoints for Enterobacteriaceae
for both mecillinam and co-amoxiclav were given as
≤8 mg/L as sensitive and ≥8 mg/L as resistant. However
the British Society of Antimicrobial Chemotherapy states
that an MIC of ≥32 mg/L for co-amoxiclav is suitable
for UTIs but not systemic infections, due to the activity
of clavulanate alone. Mecillinam concentrations in urine
after 400 mg taken orally has been reported to be above
100 mg/L after 6-h. Co-amoxiclav has also been found
to have levels above the MIC in human serum during
the first 6 h [23]. Therefore the EUCAST breakpoints
were used to determine if the isolate was sensitive or re-
sistant to both antibiotic agents. The red line in Figs. 1
and 2 illustrate the EUCAST breakpoint of 8 mg/L.
Results
Sixty-nine percent of patients (N = 66) with urinary
ESBL isolates were female. The mean age of females was
66 years compared with a mean age of 74 years for
males. Thirty-six percent of isolates originated from pri-
mary care, hospital inpatients (26 %), and nursing homes
(24 %). The vast majority of ESBL isolates were E. coli
(80 %) (Tables 1 and 2).
The E tests for mecillinam and co-amoxiclav had con-
centration ranges from 0.16 mg/L up to 256 mg/L. The
mean inhibitory concentration (MIC) of mecillinam
ranged from 0.25 to 256 mg/L, while co-amoxiclav MICs
ranged from 6 to 256 mg/L. The MICs of mecillinam
and co-amoxiclav were recorded and the total counts of
the MIC were calculated. Distribution charts were con-
structed from this data (Figs. 1 and 2).
The percentage of isolates resistant to mecillinam and
co-amoxiclav was found to be 5.26 % and 94.74 % respect-
ively [24]. Four of five isolates were E. coli and were resist-
ant to co-amoxiclav. Isolate number 513 was a Klebsiella
species. These isolates were tested using the checkerboard
technique for synergy between co-amoxiclav and mecilli-
nam. The MIC was reduced significantly in isolates 842
and 513 in comparison to the E tests where only one drug
was used. In the checkerboard method isolate 842 was
inhibited with 24ug/ml of co-amoxiclav in combination
with 12ug/ml of mecillinam. In the E test isolate 842 was
inhibited by 12ug/ml alone but was not inhibited by co-
amoxiclav until a concentration of 48 mg/L was used.
Isolate 513 was inhibited at 24ug/ml of co-amoxiclav in
combination with 64ug/ml mecillinam in the 96 well plate.
In the E test isolate 513 was not inhibited by co-amoxiclav
O’Kelly et al. BMC Infectious Diseases  (2016) 16:620 Page 3 of 7
even at 256 mg/L. Isolates 779 and 031 did not achieve
levels of 10 % of the growth of the control. Therefore the
MIC for either or both drugs in combination was higher
than 256ug/ml. In contrast the E test results showed isolate
779 was inhibited by co-amoxiclav at 128 mg/L but the
results agreed with the checkerboard for mecillinam
(>256 mg/L). The E test showed that 031 was inhibited
by 12 mg/L of mecillinam but was not inhibited by co-
amoxiclav even at 256 mg/L. The FIC is correct in that
no positive difference occurred when the two antibiotics
were used in combination. Isolate 349 was inhibited by
128 mg/L of mecillinam alone and also in combination
with co-amoxiclav (between 6-256 ug/ml) in the 96 well
plate. The E test results showed mecillinam did not inhibit
the isolate at even 256 mg/L but co-amoxiclav inhibited
349 at 128 mg/L alone.
Discussion
The increasing prevalence of clinically significant anti-
biotic resistant bacteria, especially for those resistant to
multiple classes of antibiotics, makes appropriate anti-
microbial treatment challenging [25, 26]. Many patho-
gens resistant to first line agents, then require broader
spectrum, more expensive agents with less favorable safety
profiles, which in turn accelerates the generation of multi
drug resistant (MDR) pathogens, where no agents may be
available to treat infections caused by these microorgan-
isms. As the ESBL resistance mechanism is commonly
expressed by plasmid encoded B lactamases, resistance can
be easily transferred between other bacterial species by
horizontal gene transfer. These plasmids frequently carry
genes encoding for resistance to other antibiotic classes.
Unlike methicillin resistant Staphylococcus aureus, the
resistant Gram-negative bacteria commonly colonise the
bowel and there is no available decolonization procedure.
Long-term colonization by these bacteria ensures these pa-
tients remain a potential source of transmission for many
years, with potentially indefinite requirement for isolation
and contact precautions [27, 28].
Fig. 1 Distribution of the mean inhibitory concentration (MIC) of 95
Extended spectrum beta-lactamase (ESBL) producing isolates. EUCAST
break-point of 8 mg/L demonstrated by red vertical line
Fig. 2 Distribution of the mean inhibitory concentration (MIC) of 95
Extended spectrum beta-lactamase (ESBL) producing isolates. EUCAST
break-point of 8 mg/L demonstrated by red vertical line
Table 1 Clinico-demographic profile of patients isolated with
extended-spectrum beta lactamase producing urinary infections
Average age of patients (yrs) % N =
Female 66.25 n.a.
Male 74.65 n.a.
Source of Isolation of UTI
Emergency Department 14 13
General Practice 36 34
Inpatient Wards 26 25
Nursing Home 24 23
Species Isolated
Klebsiella pneumoniae 20 19
Escherichia coli 80 76
Table 2 Fractional inhibitory concentration (FIC) of the five
extended-spectrum beta lactamase producing isolates which
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There is an urgent need for more research into new
agents that are effective against ESBLs and other resistant
bacteria. With the increase in multidrug and carbapenem-
resistant microorganisms, there is a need to minimize car-
bapenem use and they should not be first-line choice for
treating ESBLs [29]. Europe-wide antimicrobial drug resist-
ance rates remain high. A Greek study carried out in 2007
demonstrated CRE in 70 % of hospitals. Pan-drug resistant
K. pneumoniae have also been reported in the same popu-
lation. The use of mecillinam for UTIs is promising as piv-
mecillinam achieves high levels in urine, has a low
resistance profile and inhibited 94.74 % of the ESBLs in this
study. However, a broader clinical evaluation in an Irish pa-
tient population is required before clinical use can be advo-
cated. Mecillinam like other penicillins, has low toxicity like
other penicillins and is also safe to use for the treatment of
UTIs in pregnancy [30]. Mecillinam is poorly absorbed
from the gastrointestinal tract but pivmecillinam is well
absorbed. Pivmecillinam reaches serum concentrations of
3ug/ml 1.5 h after 200 mg taken orally [31].
Inappropriate use of broad-spectrum antibiotics such
as carbapenems adds to the problem of antimicrobial
resistance as well as being responsible for a rise in
C. difficile infections and healthcare costs. This study showed
thatmecillinam alone has good in vitro activity against clinical
isolates of ESBL producing E. coli andKlebsiella.
Carbapenems are often used to treat UTIs caused by
ESBLs; however this has been shown to lead to further
resistance and will exacerbate the CRE problem. Invasive
CRE infections have limited therapeutic options with
mortality rates in excess of 40 % [32]. Pivmecillinam,
widely used in Scandinavian countries for treating un-
complicated UTIs has a good safety profile [33]. Side ef-
fects of mecillinam include rash, nausea and vomiting.
Surveillance in countries that strictly limit pivmecillinam
for acute uncomplicated UTIs has shown low resistance
in the community despite widespread use for more than
20 years [16]. There are reports of mecillinam resistance
in E. coli; one mechanism is increased levels of ppGpp, a
nucleotide effector [34]. Other studies have shown a low
probability of future clonal spread of mecillinam resist-
ance due to little association of resistance due to specific
clonal groups. Other authors found that mecillinam re-
sistance is not associated with ESBL production [35, 36].
In this study only 5.36 % of ESBLs that were E tested
were resistant to mecillinam according to the EUCAST
breakpoints with only two isolates having an MIC of
>256 mg/L. This may be due the fact that mecillinam is
only slightly affected by TEM and SHV1, which are the
most frequent beta lactamases found in E. coli. In a
French study, clinical efficiency was high with pivmecil-
linam and independent of MIC, which suggests suscep-
tibility testing for UTIs caused by E. coli is not required
with pivmecillinam, and could possibly be given
empirically [17]. The results of the E tests with coa-
moxiclav show that only 2.11 % of isolates were suscep-
tible to the drug according to the CLSI breakpoints,
however according to the BSAC breakpoints, 25 % would
be effective treatment of UTIs. Resistance to coamoxiclav
is common and in a Spanish study 30.6 % of its ESBLs
population were non-susceptible. The principle risk factor
in that study was previous use of coamoxiclav, confirming
that increased consumption leads to increased resistance.
Resistance mechanisms of E. coli to coamoxiclav include
B-lactamase overproduction, AmpC cephalosporinase hy-
perproduction and inhibitor-resistant penicillinases [37].
Resistance is acquired by clonal and non-clonal spread,
dissemination of mobile elements with different bla genes
and eventual mutations in individuals organisms [38].
Coamoxiclav alone was ineffective against 97.89 % of
the isolates tested and should not be used alone for
treatment of ESBL positive UTIs, however, the combin-
ation of coamoxiclav and mecillinam decreased the MIC
significantly compared to mecillinam or coamoxiclav
alone in three isolates. However two isolates had higher
MICs with the combination of the two antibiotics com-
pared to treatment with one antibiotic. For isolate 779
the coamoxiclav MIC increased from 128 mg/L alone to
>256ug/ml when combined with mecillinam. Similarly
but more worryingly isolate 031 was inhibited by 12 mg/
L of mecillinam alone in the E test but was not inhibited
by 256ug/ml in combination with coamoxiclav. The re-
sults for the mecillinam and coamoxiclav only in the 96
well plate differed to the results of the drugs alone in
the E test. It is conceivable that some of these infections
could represent identical bacterial strains, however, patients
were disparate in time and place, and therefore it is likely
that they represent different strains. This demonstrates that
the combination of coamoxiclav and pivmecillinam on
different species that produce ESBLs could be beneficial.
However, further studies using mecillinam monotherapy or
in combination with clavulanic acid, would benefit with a
larger sample size to improve statistical power.
Conclusion
Pivmecillinam alone appears to be a suitable treatment
for UTIs due to ESBL producing Enterobacteriaceae es-
pecially lower UTIs. Resistance to this agent has been
low even though it has been used for treating UTIs in
Nordic countries for more than 20 years. In the future
pivmecillinam in combination with coamoxiclav, would
seem to be an appropriate treatment alternative for
Irish ESBL infections and will also help reduce carba-
penem usage, which in turn should help reduce the
generation of CRE producing organisms. However for
combination therapy further clinical evaluation would
be required before clinical use could be advocated.
O’Kelly et al. BMC Infectious Diseases  (2016) 16:620 Page 5 of 7
Abbreviations
CRE: Carbapenem Resistant Enterobacteriaceae; ESBL: Extended spectrum beta
lactamase; EUCAST: European Committee on Antimicrobial Susceptibility
Testing; FIC: Fractional inhibitory concentration; MIC: Mean inhibitory
concentration; PBP: Penicillin binding protein; SHV: Sulfhydryl variable
beta-lactamases; TEM: Temoneira beta-lactamases; UTI: Urinary tract infection
Acknowledgements
We would like to acknowledge the tremendous work of the laboratory
microbiologists who identified all the organisms and conducted the original
susceptibility testing for all the organisms used in this study.
Funding
No funding was received at any stage for this study.
Availability of data and materials
The vast majority of the data supporting our findings are contained within
the manuscript. The remaining data will not be shared at present as it lies
central to future research and manuscripts. Identifying/confidential patient
data would not be available.
Authors’ contributions
All authors have read and approved the manuscript. FOK, SK and JF made
substantial contributions to conception and design, or acquisition of data, or
analysis and interpretation of data. RPM and JAT were involved in drafting
the manuscript or revising it critically for important intellectual content. JAT
and JF gave final approval of the version to be published.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study involving the use of patient-derived samples is in line with the
Helsinki Declaration. Ethical approval was granted by the Tallaght University
Hospital Ethics Committee. Written consent was obtained at the outset and
participants could withdraw from the study at any time.
Author details
1Department of Clinical Microbiology, AMNCH, Tallaght Hospital, Dublin 24,
Ireland. 2Department of Urological Surgery, AMNCH, Tallaght Hospital, Dublin
24, Ireland.
Received: 4 September 2015 Accepted: 23 August 2016
References
1. Dhillon RH-P, Clark J. ESBLs: a clear and present danger? Crit Care Res Pract.
2012;2012:625170.
2. Livermore DM, Hawkey PM. CTX-M: changing the face of ESBLs in the UK.
J Antimicrob Chemother. 2005;56:451–4.
3. Fennell J, et al. Increasing prevalence of ESBL production among Irish
clinical Enterobacteriaceae from 2004 to 2008: an observational study. BMC
Infect Dis. 2012;12:116.
4. Linhares I, Raposo T, Rodrigues A, Almeida A. Frequency and antimicrobial
resistance patterns of bacteria implicated in community urinary tract
infections: a ten-year surveillance study (2000–2009). BMC Infect Dis.
2013;13:19.
5. Thomson KS. Extended-spectrum-beta-lactamase, AmpC, and
Carbapenemase issues. J Clin Microbiol. 2010;48:1019–25.
6. Kanj SS, Kanafani ZA. Current concepts in antimicrobial therapy against
resistant gram-negative organisms: extended-spectrum beta-lactamase-
producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae,
and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc.
2011;86:250–9.
7. Pobiega M, et al. Molecular characterization and drug resistance of
Escherichia coli strains isolated from urine from long-term care facility
residents in Cracow, Poland. Med Sci Monit. 2013;19:317–26.
8. Martinez P, Garzón D, Mattar S. CTX-M-producing Escherichia coli and
Klebsiella pneumoniae isolated from community-acquired urinary tract
infections in Valledupar, Colombia. Braz J Infect Dis. 2012;16:420–5.
9. Azap OK, et al. Risk factors for extended-spectrum beta-lactamase positivity
in uropathogenic Escherichia coli isolated from community-acquired urinary
tract infections. Clin Microbiol Infect. 2010;16:147–51.
10. Pelly H, et al. Outbreak of extended spectrum beta-lactamase producing E.
coli in a nursing home in Ireland, May 2006. Euro Surveill. 2006;11:E060831.1.
11. Ludden C, et al. Colonisation with ESBL-producing and carbapenemase-
producing Enterobacteriaceae, vancomycin-resistant enterococci, and
meticillin-resistant Staphylococcus aureus in a long-term care facility over
one year. BMC Infect Dis. 2015;15:168.
12. EARS-Net Report, Quarter 1-4 2015. Health Protection Surveillance Centre 2016.
http://www.hpsc.ie/A-Z/MicrobiologyAntimicrobialResistance/European
AntimicrobialResistanceSurveillanceSystemEARSS/EARSSSurveillanceReports/
2015Reports/File,15214,en. Accessed June 2016.
13. Al-Assil B, Mahfoud M, Hamzeh AR. Resistance trends and risk factors of
extended spectrum β-lactamases in Escherichia coli infections in Aleppo,
Syria. Am J Infect Control. 2013;41:597–600.
14. Hoşbul T, et al. In vitro activity of fosfomycin trometamol in the treatment
of Escherichia coli related uncomplicated urinary tract infections. Mikrobiyol
Bul. 2009;43:645–9.
15. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for
the treatment of multiresistant Gram-negative bacteria. J Antimicrob
Chemother. 2010;65(Suppl 3):iii25–33.
16. Auer S, Wojna A, Hell M. Oral treatment options for ambulatory patients
with urinary tract infections caused by extended-spectrum-beta-
lactamase-producing Escherichia coli. Antimicrob Agents Chemother.
2010;54:4006–8.
17. Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore D. Activity of
mecillinam against ESBL producers in vitro. J Antimicrob Chemother. 2006;
57:367–8.
18. Graninger W. Pivmecillinam–therapy of choice for lower urinary tract
infection. Int J Antimicrob Agents. 2003;22(Suppl 2):73–8.
19. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems:
past, present, and future. Antimicrob Agents Chemother. 2011;55:4943–60.
20. Meletiadis J, Pournaras S, Roilides E, Walsh TJ. Defining fractional inhibitory
concentration index cutoffs for additive interactions based on self-drug
additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo
correlation data for antifungal drug combinations against Aspergillus fumi.
Antimicrob Agents Chemother. 2010;54:602–9.
21. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory
concentration (FIC) index as a measure of synergy. J Antimicrob Chemother.
1983;11:427–33.
22. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different
in vitro methods of detecting synergy: time-kill, checkerboard, and E test.
Antimicrob Agents Chemother. 1996;40:1914–8.
23. Prieto J, et al. In vitro activities of co-amoxiclav at concentrations achieved
in human serum against the resistant subpopulation of heteroresistant
Staphylococcus aureus: a controlled study with vancomycin. Antimicrob
Agents Chemother. 1998;42:1574–7.
24. Neuzillet Y, Naber KG, Schito G, Gualco L, Botto H. French results of the
ARESC study: clinical aspects and epidemiology of antimicrobial resistance
in female patients with cystitis. Implications for empiric therapy. Med Mal
Infect. 2012;42:66–75.
25. Cullen IM, et al. The changing pattern of antimicrobial resistance within
42,033 Escherichia coli isolates from nosocomial, community and urology
patient-specific urinary tract infections, Dublin, 1999–2009. BJU Int. 2012;109:
1198–206.
26. Frakking FNJ, et al. Appropriateness of empirical treatment and outcome in
bacteremia caused by extended-spectrum-β-lactamase-producing bacteria.
Antimicrob Agents Chemother. 2013;57:3092–9.
27. Fan N-C, et al. Rise of community-onset urinary tract infection caused by
extended-spectrum β-lactamase-producing Escherichia coli in children.
J Microbiol Immunol Infect. 2013. doi:10.1016/j.jmii.2013.05.006.
28. Yamamoto A. Extended-spectrum β-lactamase (ESBL)-producing Escherichia
coli is frequently detected as a pathogen of urinary tract infection in
nursing home residents. Nihon Ronen Igakkai Zasshi. 2011;48:530–8.
29. Dewar S, Reed LC, Koerner RJ. Emerging clinical role of pivmecillinam in the
treatment of urinary tract infection in the context of multidrug-resistant
bacteria. J Antimicrob Chemother. 2014;69:303–8.
O’Kelly et al. BMC Infectious Diseases  (2016) 16:620 Page 6 of 7
30. Heikkilä A, Pyykkö K, Erkkola R, Iisalo E. The pharmacokinetics of mecillinam
and pivmecillinam in pregnant and non-pregnant women. Br J Clin
Pharmacol. 1992;33:629–33.
31. Andrews J, Kendall MJ, Mitchard M. Factors influencing the absorption and
disposition of mecillinam and pivmecillinam in man. Br J Clin Pharmacol.
1976;3:627–32.
32. Kumarasamy KK, et al. Emergence of a new antibiotic resistance mechanism
in India, Pakistan, and the UK: a molecular, biological, and epidemiological
study. Lancet Infect Dis. 2010;10:597–602.
33. Lampri N, et al. Mecillinam/clavulanate combination: a possible option for
the treatment of community-acquired uncomplicated urinary tract
infections caused by extended-spectrum β-lactamase-producing Escherichia
coli. J Antimicrob Chemother. 2012;67:2424–8.
34. Poulsen HO, Johansson A, Granholm S, Kahlmeter G, Sundqvist M. High
genetic diversity of nitrofurantoin- or mecillinam-resistant Escherichia coli
indicates low propensity for clonal spread. J Antimicrob Chemother. 2013;
68:1974–7.
35. Sougakoff W, Jarlier V. Comparative potency of mecillinam and other beta-lactam
antibiotics against Escherichia coli strains producing different beta-lactamases.
J Antimicrob Chemother. 2000;46(Suppl 1):9–14. discussion 63–5.
36. Kariuki S, et al. Escherichia coli from community-acquired urinary tract
infections resistant to fluoroquinolones and extended-spectrum beta-
lactams. J Infect Dev Ctries. 2007;1:257–62.
37. Rodríguez-Baño J, et al. Epidemiological and clinical complexity of
amoxicillin-clavulanate-resistant Escherichia coli. J Clin Microbiol. 2013;
51:2414–7.
38. Miyakis S, Pefanis A, Tsakris A. The challenges of antimicrobial drug
resistance in Greece. Clin Infect Dis. 2011;53:177–84.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
O’Kelly et al. BMC Infectious Diseases  (2016) 16:620 Page 7 of 7
